Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
Harvard Business School
McKesson
US Army
Dow
Chinese Patent Office
Merck
Accenture

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,655,636

« Back to Dashboard

Which drugs does patent 7,655,636 protect, and when does it expire?

Patent 7,655,636 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 7,655,636
Title:Use of A2A adenosine receptor agonists
Abstract:The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, -- an adenosine A.sub.2A receptor agonist -- to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.
Inventor(s): Gordi; Toufigh (Sunnyvale, CA), Olmsted; Ann Walls (Palo Alto, CA), Lieu; Hsiao Dee (Burlingam, CA), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:11/253,322
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,655,636

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,655,636

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,106,029 Use of A.sub.2A adenosine receptor agonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
QuintilesIMS
Boehringer Ingelheim
AstraZeneca
Moodys
Merck
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.